Recombinant Chimeric (Human/Mouse) Antibody (KM3060) is capable of binding to CCR4. The Fc fragments prepared from KM3060 and KM3575 will be simply designated Fuc (+) and Fuc (−), respectively.
Figure 1 Kaplan-Meier survival plot of SCID mice inoculated with CCR4/EL4 cells.
Indicated treatments were given i.p. on 1, 3, and 5 days after tumor inoculation. A, mice were engrafted with human peripheral blood mononuclear cells 4 days before tumor inoculation. B, mice were not engrafted with human peripheral blood mononuclear cells for the control experiment. Each group consisted of five or six mice. The mean survival time (MST) of each group were shown in the inset; bars, ±SD. Similar results were found in two repeat experiments. Significant differences between experimental groups are indicated by * (P<0.05), ** (P<0.01), or ns (not significant).
Niwa, R., Shoji-Hosaka, E., Sakurada, M., Shinkawa, T., Uchida, K., Nakamura, K., ... & Shitara, K. (2004). Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer research, 64(6), 2127-2133.
Figure 2 Antitumor activity of KM2760 and KM3060 in murine effector system. A, antibody-dependent cellular cytotoxicity of KM2760 and KM3060 with murine effector cells.
In vitro cytotoxicities of the two IgG1s were determined in 51Cr release assay using interleukin 2-activated splenocytes (upper) or thioglycollate-induced macrophages (lower) as effector cells. Cytotoxicity (%) is indicated on the Y axis as mean (n = 3); bars, ± SD. Dashed lines indicate the natural cytotoxicity in the absence of antibody (29% for splenocyte cytotoxicity and 2.6% for macrophage cytotoxicity). E:T ratios are shown above each panel. In splenocyte cytotoxicity assay, similar data were also obtained with E:T = 30, with 15% natural cytotoxicity and very weak antibody-dependent cytotoxicities for the two IgG1s, which were not significantly different from each other (data not shown). B, effect of KM2760 and KM3060 on syngeneic disseminated tumor. Experimental metastases were induced by i.v. inoculation of CCR4/EL4 cells into C57BL/6 mice. Of the two IgG1s or control saline, 0.1 or 1 μg was injected on 1, 3, and 5 days after inoculation i.v. Each group consisted of five or six mice. On day 12, livers (upper) and kidneys (lower) were taken from all mice including healthy ones that did not receive tumor inoculation (naive) and measured their relative weight as a percentage to the total body weight to evaluate the metastasis. Horizontal lines represent mean value in each group. Treated versus control (%) of each animal group were shown above each panel. Significant differences between the two IgG1s are indicated by * (P<0.05) or ** (P<0.01). Similar results were found in two repeat experiments. C, effect of natural killer cell-depletion on the antitumor activities of KM2760 and KM3060. To deplete natural killer cells, all mice were additionally given anti-asialo GM1 antisera (50 g, i.p.) on day -3, -1, and 1 to the same experimental protocol as described in B.
Niwa, R., Shoji-Hosaka, E., Sakurada, M., Shinkawa, T., Uchida, K., Nakamura, K., ... & Shitara, K. (2004). Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer research, 64(6), 2127-2133.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-187 | Human Anti-CCR4 Recombinant Antibody (TAB-187) | Neut, ELISA, IF, IP, FuncS, FC, ICC | Human IgG1, κ |
TAB-1530CL | Human Anti-CCR4 Recombinant Antibody (TAB-1530CL) | Depletion, FuncS | Human IgG4 |
TAB-1530CL-S(P) | Human Anti-CCR4 Recombinant Antibody; scFv Fragment (TAB-1530CL-S(P)) | Depletion, FuncS | Human scFv |
TAB-1530CL-F(E) | Human Anti-CCR4 Recombinant Antibody; Fab Fragment (TAB-1530CL-F(E)) | Depletion, FuncS | Humanized Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
AGTO-G005D | Anti-CCR4 immunotoxin (scFv)-DT | Cytotoxicity assay, Function study |
CAT | Product Name | Application | Type |
---|---|---|---|
PFBZ-142 | Human Anti-CCR4 Recombinant Antibody (clone KM3060); Fab Fragment | WB | Chimeric (mouse/human) Fab |
HPAB-0141-LSX-S(P) | Mouse Anti-CCR4 Recombinant Antibody; scFv Fragment (HPAB-0141-LSX-S(P)) | ELISA, WB, FC | Mouse scFv |
HPAB-0143-LSX-S(P) | Human Anti-CCR4 Recombinant Antibody; scFv Fragment (HPAB-0143-LSX-S(P)) | ELISA, WB, FC | Human scFv |
HPAB-0144-LSX-S(P) | Human Anti-CCR4 Recombinant Antibody; scFv Fragment (HPAB-0144-LSX-S(P)) | ELISA, WB, FC | Human scFv |
HPAB-1268WJ-S(P) | Mouse Anti-CCR4 Recombinant Antibody; scFv Fragment (HPAB-1268WJ-S(P)) | ELISA, WB, FC | Mouse scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-1521CL-F(E) | Anti-Human CCR4 Recombinant Antibody Fab Fragment (208) | FC, Inhib | Human antibody |
TAB-1522CL-F(E) | Anti-Human CCR4 Recombinant Antibody Fab Fragment (306) | FC, Inhib | Human antibody |
TAB-1523CL-F(E) | Anti-Human CCR4 Recombinant Antibody Fab Fragment (308) | FC, Inhib | Human antibody |
TAB-1524CL-F(E) | Anti-Human CCR4 Recombinant Antibody Fab Fragment (406) | FC, Inhib | Human antibody |
TAB-1525CL-F(E) | Anti-Human CCR4 Recombinant Antibody Fab Fragment (501) | FC, Inhib | Human antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-0141-LSX | Mouse Anti-CCR4 Recombinant Antibody (HPAB-0141-LSX) | ELISA, WB, FC, ADCC, CDC, FuncS | Mouse IgG2b |
HPAB-0143-LSX | Human Anti-CCR4 Recombinant Antibody (HPAB-0143-LSX) | ELISA, WB, FC, ADCC, CDC, FuncS | Human IgG |
HPAB-0144-LSX | Human Anti-CCR4 Recombinant Antibody (HPAB-0144-LSX) | ELISA, WB, FC, ADCC, CDC | Human IgG |
HPAB-0145-LSX | Human Anti-CCR4 Recombinant Antibody (HPAB-0145-LSX) | ELISA, WB, FC, ADCC, CDC | Human IgG |
HPAB-0146-LSX | Human Anti-CCR4 Recombinant Antibody (HPAB-0146-LSX) | ELISA, IF | Chimeric (mouse/human) IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-0141-LSX-F(E) | Mouse Anti-CCR4 Recombinant Antibody; Fab Fragment (HPAB-0141-LSX-F(E)) | ELISA, WB, FC | Mouse Fab |
HPAB-0143-LSX-F(E) | Human Anti-CCR4 Recombinant Antibody; Fab Fragment (HPAB-0143-LSX-F(E)) | ELISA, WB, FC | Humanized Fab |
HPAB-0144-LSX-F(E) | Human Anti-CCR4 Recombinant Antibody; Fab Fragment (HPAB-0144-LSX-F(E)) | ELISA, WB, FC | Humanized Fab |
HPAB-0145-LSX-F(E) | Human Anti-CCR4 Recombinant Antibody; Fab Fragment (HPAB-0145-LSX-F(E)) | ELISA, WB, FC | Humanized Fab |
HPAB-0146-LSX-F(E) | Human Anti-CCR4 Recombinant Antibody; Fab Fragment (HPAB-0146-LSX-F(E)) | ELISA, IF | Chimeric (mouse/human) Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
AFC-TAB-187 | Afuco™ Anti-CCR4 Recombinant Antibody (AFC-TAB-187), ADCC Enhanced | Neut, ELISA, IF, IP, FuncS, FC | Human IgG1, κ |
There are currently no Customer reviews or questions for PABZ-142. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.